Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126185171 | 12618517 | 1 | I | 20160708 | 0 | 20160802 | 20160802 | DIR | 41.00 | YR | F | N | 0.00000 | 20160801 | Y | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126185171 | 12618517 | 1 | PS | AMPYRA | DALFAMPRIDINE | 1 | Oral | D | D | TCNV | 20180430 | 0 | 10 | MG | Q12H | ||||
| 126185171 | 12618517 | 2 | C | RITUXIMAB | RITUXIMAB | 1 | 0 | ||||||||||||
| 126185171 | 12618517 | 4 | C | CITALOPRAM | CITALOPRAM HYDROBROMIDE | 1 | 0 | ||||||||||||
| 126185171 | 12618517 | 6 | C | OXYBUTYNIN | OXYBUTYNIN | 1 | 0 | ||||||||||||
| 126185171 | 12618517 | 8 | C | OXAZEPAM. | OXAZEPAM | 1 | 0 | ||||||||||||
| 126185171 | 12618517 | 10 | C | IBUPROFEN. | IBUPROFEN | 1 | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126185171 | 12618517 | 1 | Multiple sclerosis |
Outcome of event
| no results found |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126185171 | 12618517 | Laboratory test abnormal |
Reporting Sources (this data is often not reported and may therefore be missing here)
| Event ID | CASEID | RPSR COD |
|---|---|---|
| 126185171 | 12618517 | HP |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 126185171 | 12618517 | 1 | 201511 | 0 |